SAHPRA Approves Pfizer’s Paxlovid COVID-19 Treatment
SAHPRA announced the registration of Paxlovid COVID-19 treatment, an anti-viral medicine manufactured by Pfizer, to treat COVID-19. This is a 5-day oral treatment for mild to moderate COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.
International sources provide guidelines regarding prescribing in liver and kidney disease as well as possible drug interactions including statin therapy, anticoagulation and some hormonal birth control treatments.
Recent Posts
Biologic Dispensing Implementation Gaps Challenge Patient Access to Care
Biologic dispensing implementation gaps are undermining equitable access to advanced therapies for inflammatory bowel disease across Portugal’s public hospitals. Despite clear legislative changes, institutions continue to reject prescriptions for biologics written by private specialists, forcing ...
Curative Therapy Commercialization Gap and Global Access Challenges
The curative therapy commercialization gap remains one of healthcare’s most stubborn contradictions: cell and gene therapies can deliver complete disease resolution, yet structural, financial, and infrastructural barriers keep them from reaching most patients who need them. This disconnect is esp...
Transatlantic Reference Pricing Innovation and Its Impact on Global Pharmaceutical Dynamics
The transatlantic reference pricing innovation is fundamentally altering pharmaceutical revenue expectations and patient access on both sides of the Atlantic. By anchoring U.S. reimbursement to the second-lowest net price among a basket of wealthy nations, the Most Favored Nation (MFN) policy cre...